NCT07815691|RecruitingPhase 2DMCFDA Drug
Endocannabinoids in Reward
The Contribution of the Endocannabinoid System to Sex Differences in THC-associated Reward
Loading search results
Sponsor study identifier
interventional
78
1 country
1
Study Start
October 1, 2026
Actual (reported)Primary Completion
July 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study will examine sex differences in the effects of cannabis in people that regularly use it. Men and women that use cannabis at least 4 days a week will participate in a study involving 3 in-person visits. The first visit will be used to determine eligibility for the study. The other two visits will last 7 hours each and take place at least two days apart. Visits include administration of either THC, the chemical responsible for many of the psychoactive effects of cannabis, or a placebo; completion of questionnaires; and a 1-hour brain scan. One visit will also include a blood draw for genetic testing.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 3, 2026
Actual (reported)September 11, 2026
Actual (reported)October 1, 2026
Actual (reported)July 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
July 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Nucleus accumbens glutamate
Concentrations of nucleus accumbens glutamate measured via proton magnetic resonance spectroscopy
2 hours post-dose
Drug Effects Questionnaire (DEQ) - Like Drug Effect
Visual Analog Scale rating of subjective drug liking included in the Drug Effects Questionnaire. Score ranges from 0 (not at all) to 100 (extremely) using a 100mm line anchored with none/extreme designation.
0-7 hours post-dose
Sex differences in genetics
Blood-based DNA sample will be tested for genetic variants of interest involved in the endocannabinoid system
Day 1
Dorsal striatal glutamate
2 hours post-dose
Drug Effects Questionnaire (DEQ) - Want More
0-7 hours post-dose
Drug Effects Questionnaire (DEQ) - High
0-7 hours post-dose
Oral dronabinol capsules (40 mg)
Matched placebo capsules
Medical University of South Carolina
Charleston, South Carolina, 29403, United States
First Submitted
September 3, 2026
First Posted
September 11, 2026
Study Start
October 1, 2026
Actual (reported)Primary Completion
July 31, 2031
EstimatedLongitudinal Outpatient Treatment for Cannabis Use Disorder
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 5, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: